is a method to combine data from various sources for differential diagnosis and progression of neurodegenerative disorders.
OBJECTIVE: To apply DSI to predict clinical AD in shunted iNPH-patients in a defined population.
METHODS: 335 shunted iNPH-patients (median 74 years) were followed until death (n=185) or 6/2015 (n=150) . DSI model (including symptom profile, onset age of NPH symptoms, atrophy of medial temporal lobe in CT/MRI, cortical brain biopsy finding,
INTRODUCTION
Idiopathic normal pressure hydrocephalus (iNPH) is a progressive, potentially dementing disorder which is manifested by symptoms including impaired gait, urinary incontinence and cognitive impairment, as well as enlarged brain ventricles [1, 2] .
Apart from other neurodegenerative diseases, symptoms of iNPH can be alleviated with cerebrospinal fluid (CSF) diversion, although successful selection of patients for shunt treatment has proven to be difficult [3] [4] [5] . Patients diagnosed with iNPH have shown to often have pathological changes related to Alzheimer's disease (AD) [6] [7] [8] [9] [10] [11] [12] , which has been linked to later development of AD and dementia [13, 14] .
Previous studies indicate deterioration of cognition in iNPH patients even after shunt surgery [2, 15, 16] , but the prognostic factors of comorbid AD have not been 7 analyzed.
The Disease State Index (DSI) is a statistical tool designed for multimodal data analysis and clinical decision-making. It is capable for analysis of fragmented data and merging opaque information to well interpretable scores for individual patients and discrimination between patient groups. DSI has been previously successful in differential diagnosis of AD, predicting progression to AD among subjects with mild cognitive impairment (MCI), separating frontotemporal dementia (FTD) from AD, and working with various cohorts [17] [18] [19] [20] .
In this retrospective cohort study, we compare the occurrence of clinical AD in iNPH with general population and attempt to predict development of AD among shunted iNPH patients, using the DSI. Merging information of individual patients' baseline cortical brain biopsy, radiological markers, symptom profile, and APOE-genotype, we intend to develop a model capable of predicting patients in risk of clinical AD.
MATERIALS AND METHODS

Patients and shunt protocol
The Department of Neurosurgery in the Kuopio University Hospital (KUH) serves the defined catchment population in Eastern Finland. Since 1993, the diagnostic workup of KUH Neurosurgery for suspected NPH has included a clinical examination by a neurologist and a neurosurgeon, CT or MRI scan, and a right frontal cortical biopsy [14] . The Kuopio NPH Registry (www.uef.fi/nph) consists of 764 consecutive patients to the end of the year 2012 including baseline and follow-up data from KUH, all 8 primary health care physicians, and other local hospitals in the KUH catchment area.
Demographic data is shown in Table 1 . Patients were evaluated for suspected NPH fulfilling the following criteria: 1) 1 to 3 symptoms related to NPH: impaired cognition, gait, or urinary continence; 2) enlarged brain ventricles, i.e. Evans' index > 0.3 in CT or MRI.
Patients shunted for iNPH were included in the analysis, but those with iNPH and comorbid clinical AD at baseline were excluded from the prognostication analysis ( Figure 1 ). Selection for shunt surgery was done with 24-h intraventricular pressure (IVP) monitoring until the end of 2010 with indications for shunt: 1) a basal ICP above 10 mmHg; or 2) the presence of any A waves or more than 30% B waves during the 24-hour ICP monitoring [3, 14, 21] . Since 2011, a three-step protocol was used for shunt surgery selection: first a lumbar CSF removal of 20 ml (tap test) was performed for all patients, and 20 % improvement in gait speed was considered positive response; patients with negative tap test underwent a lumbar infusion test, where conductance of 10 or less was considered pathological [22] ; and those with negative result both in tap test and infusion test were shunted based on 24-h IVP monitoring as described above. Ventriculoperitoneal shunts (VPS) with a medium-pressure differential pressure valve until 2010 and adjustable PS Medical Strata valve since 2010 were used for shunting. The initial response to the shuntdefined as improvement in the patient's gait, memory, or urinary incontinencewas observed by the clinician 2 to 3 months after the shunt placement at the outpatient clinic.
The clinical follow-up was continued in local hospitals and by primary care physicians. Adequate follow-up data to evaluate clinical dementia was missing for 24 patients (Figure 1 ). Study population was followed for a median period of 5.3 years (range 0.2 -21), during which 185 patients died. Data from KUH archives, local hospitals, and primary care physicians was collected and causes of death were obtained from the national registries to detect development of clinical AD. AD was diagnosed according to revised NINCDS-ADRDA criteria [23] , and examinations by geriatricians and neurologists were taken in to account. Study neurologists specialized in memory disorders (AMK, ON) have evaluated the follow-up information of the study patients and verified dementia diagnoses as described before [2] . If shunt malfunction or cognitive impairment was suspected, the patients were referred for neurological and neurosurgical re-evaluation. During the follow-up, a total of 91 shunt revisions were made.
Clinical and cognitive data
Clinical symptoms included in the analysis were gait impairment, cognitive impairment, urinary incontinence, and other symptoms, such as vertigo, tremor and headache. The symptoms were further divided into three subgroups according to the time of occurrence of the symptom: 1) the first symptom; 2) the main symptom; and 3) present symptom, i.e. the symptom was present during clinical assessment. In addition, the onset age of NPH symptoms and presence of full NPH symptom triad were included. Comorbidities such as any cardiovascular disease, diabetes, or any previous neurological condition were included in the analysis. To evaluate influence of cognitive deterioration on outcome, the Mini-Mental State Examination (MMSE, range 0-30, 30 indicating good cognitive performance) was included in the analysis [24] .
Radiological data
Within the registry, patients had CT or MRI, or both imaging data available. For this analysis, data obtained by MRI was preferred over CT. Images were evaluated by radiologist visually for atrophy of left and right medial temporal lobe (Scheltens grade), white matter changes in periventricular and deep white matter, and disproportionality between sylvian and suprasylvian subarachnoid spaces [25, 26] . In addition, Evans' index was calculated.
Histological evaluation of brain biopsy
The paraffin-embedded biopsy samples were sectioned (7 µm) and stained with hematoxylin-eosin, and immunostained with monoclonal antibodies directed to amyloid beta (Aβ) (6F/3D, M0872; Dako; dilution 1:100; pretreatment 80% formic acid 1 hour) and hyperphosphorylated tau (HPτ) (AT8, 3Br-3; Innogenetics; dilution 1:30) as described previously [27] . In all samples immunoreactivity for Aβ and HPτ was graded as present or absent by a neuropathologist [28] . In total, cortical brain biopsy data was available for 331 patients, with 5 cases of inconclusive histological data.
APOE-genotyping
A PCR method was used in the analysis of APOE (n = 197), as described previously [13] . For the analysis, ε4 was classified as carrier or non-carrier.
CSF AD-biomarkers
The lumbar CSF levels of Aβ1-42, total-tau, and phosphorylated-tau181 were measured by commercial ELISA kits (Innotest β-amyloid1-42, Innotest Tau-Ag, Innotest 11 Phosphotau(181P), Innogenetics, Ghent, Belgium) according to the manufacturer's protocol, as described previously [29] . Individual CSF values of p-tau, total-tau and Aβ1-42 were included in the analysis [30] . In total, CSF data was available for 95 patients.
Reference populations
Cardiovascular Risk factors, Aging and Dementia (CAIDE) is a population-based study in the Kuopio and Joensuu town areas in Eastern Finland. The study design has been previously described in detail [31] . In addition, primary causes of death and total count of deceased population were obtained from Statistic Finland registry [33] . Primary causes of death were obtained from the year 2015, as the end of follow-up in study population was in June 2015
Dementia as a primary cause of death consisted of ICD-10 diagnoses of F01, F03, G30, and R54. Dementia was a primary cause of death in 7624 (15.7 %) cases of 12 
Disease State Index
The DSI is a statistical method that allows us to compare patient's data to cases with a known diagnosis [18] . The values, ranging from zero to one, indicate similarity to the positive group, which is in this case the development of subsequent AD. All available data from patients, whether continuous, binary or categorical, can be included in the DSI analysis, and the method does not require a complete dataset but can tolerate missing values, making it ideal for clinical work or a retrospective registry study.
The DSI method is based on comparison of patients' measurements between two groups. The measurements from patients with a known diagnosis from these two groups form two distributions to which the patient under analysis is compared. The patient's similarity to the positive group is calculated using a fitness function for each taken measurement. The fitness function is defined as:
= +
It is calculated for each measurement value using the value as the point of classification threshold. If there are no false negatives, fitness is 0, while at the point when there are no false positives, fitness becomes 1. This is the DSI value for the individual measurements. Additionally, the relevance for each measurement is calculated. Relevance depicts the ability to discriminate between two groups with values ranging from 0, meaning no difference between groups to 1, meaning a complete separation of the groups. The relevance is computed as
where the sensitivity and specificity are obtained by classifying the training data using the measure. DSI is first calculated for each measurement (e.g. Amyloid β positivity), then for each measurement group (e.g. Cortical brain biopsy) and then all groups together as total DSI.
A total DSI value is computed by averaging the DSI values of each measure by applying weighting with the relevance values:
This method has been described in detail previously [18] .
Statistical analysis
Groups used for this analysis were patients with clinical AD and without clinical AD at the end of the follow-up (Figure 1 
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RESULTS
In total 70 out of 335 shunted iNPH patients ( Table 2 ). Significant analyzed factors for the DSI model were age (AUC = 0.64), clinical symptoms (AUC = 0.66), radiology (AUC = 0.66), cortical brain biopsy (AUC = 0.69), and APOE-genotyping (AUC = 0.62). Individual measurements are presented in Supplementary Table 1 . Excluding cortical brain biopsy from DSI model lowered its effectiveness to AUC of 0.70 and accuracy of 0.66 (Supplementary Table   2 ). Stratification analysis of the model used is presented in Figure 3 and in Supplementary Table 3 . Distribution of DSI values between groups is shown in Pathological findings in cortical brain biopsy were the most effective predictive factor of clinical AD in our analysis (AUC = 0.69). Aβ immunoreactivity was more predictive (AUC = 0.65) than HPτ (AUC = 0.57), with higher occurrence in later clinical AD group. Presence of Aβ and HPτ pathology has been linked to later development of AD [6] as well as hampered shunt surgery outcome [8, 9, 34] . HPτ immunoreactivity was more frequent in AD group, and when combined with Aβ contributed to increased effectiveness of separation in cortical brain biopsy measurement group.
Interestingly, 31% of the iNPH cases without subsequent AD had a positive biopsy for Aβ with an additional 5% being positive for both Aβ and HPτ. These patients will likely develop subsequent AD with longer follow-up. Furthermore, 32% of cases who developed subsequent, clinical AD were negative for Aβ and HPτ on their biopsy.
This highlights the progressive nature of AD, and also suggest that although clinical presentation could be alike to AD there can be mixed pathology behind the developed cognitive impairment, e.g. vascular dementia [8] . We conclude that obtaining brain biopsy during shunt insertion for iNPH patients is substantial aid for later prediction of clinical AD.
The group of combined clinical symptoms was the second most effective analyzed risk (AUC = 0.66). Combining single factors to a group was effective, as the most powerful was cognitive impairment as main symptom (AUC = 0.64). Onset age of NPH symptoms performed equally (AUC = 0.64), but its impact on final model was limited, as the effectiveness of the DSI remained nearly the same in drop-out analysis. Patients developing subsequent clinical AD were characterized by older onset age of NPH symptoms, less frequent gait impairment as the most disturbing symptom, and more often cognitive impairment as the first symptom, main symptom, and present symptom at baseline. Cognitive impairment as part of NPH symptoms has been linked to later development of dementia, mostly caused by AD [14] . Our study suggests that clinical symptoms are beneficial for clinical AD prediction.
From individual factors, atrophy of medial temporal lobe (MTA) was the most discriminating (AUC = 0.66). Patients with later clinical AD had more severe baseline
MTA measured with Scheltens scale when compared to the patients, who did not develop clinical AD. MTA's effectiveness to predict further progression of AD dementia at prodromal stage has been well documented [35, 36] . It would be feasible to assume that MTA could be used for iNPH shunt surgery outcome prediction, as development of AD hampers the prolonged response to treatment [27] . However, this has not been the case [3, 26] , which may be result of the limited follow-up time of 3 months at outpatient clinic. Although MTA was not measured for the whole cohort (n = 119), we consider that the baseline visual assessment of MTA can be used in conjunction with other factors to predict later development of clinical AD. However, it should be noted that the atrophy of MTA might be overestimated in iNPH especially prior to shunt surgery [21] . 19 APOE ε4 allele is the most important independent genetic risk factor for late onset AD [37] . Previously it has been shown to correlate with cortical brain biopsy Aβ plaques, and to predict later AD with relatively high specificity (77 %) [13] . In current study, occurrence of APOE ε4 allele was higher among patients who developed clinical AD. Its effectiveness was relatively weak (AUC = 0.59), but as previously reported, specificity of APOE ε4 allele was highest among analyzed risk factors (81 %). We found APOE-genotyping useful for the DSI model.
Interestingly, MMSE and lumbar CSF biomarkers were not significant in our analysis.
Baseline values of MMSE were at the same level among comparison groups. As MMSE has been shown to be insensitive to AD progression, it would be interesting to study Consortium to Establish a Registry for Alzheimer's Disease Neuropsychological Battery (CERAD-NB) results and its subtests, especially episodic memory, before and after shunt treatment [38] . We may hypothesize that later development of AD would be predicted by only modest or no cognitive improvement in CERAD-NB postoperatively. Lumbar CSF levels of p-tau 181, total tau, and amyloid beta1-42 were also not significant in the analysis, and there was only a slight trend of lower amyloid beta1-42 among clinical AD group. Lumbar CSF biomarkers have been under rigorous research for iNPH shunt treatment response, but with mixed results [39, 40] .
Although lumbar CSF biomarkers of neurodegeneration are strongly associated with AD [41] , it does not seem to apply in our cohort of patients shunted for iNPH possibly due to obfuscating effect of impaired CSF clearance [42] , or because of limited number of patients with CSF data available. As patients with suspected NPH have not developed dementia, comorbid AD in this subgroup is in very early stage, possibly rendering lumbar CSF analysis inoperative. We think this highlights the 20 usefulness of cortical biopsy among these patients. As it is evident that occurrence of clinical AD is increased in patients with iNPH, further study is needed to clarify whether AD pathology is a real risk factor for iNPH or iNPH a risk factor for AD. A pathophysiological link has been proposed [43] and changes in amyloid β processing is detected [44] but CSF shunt does not improve symptoms of AD (without concomitant iNPH) [45] . For future prospects, ratio of Aβ42/40 should be evaluated with iNPH cohort [46] and prognosticators for other concomitant dementias should be examined [47] .
There was a tendency of higher shunt revision rate among patients without later clinical AD, although statistically insignificant. There were no differences between Joensuu town areas in Eastern Finland [25] . Primary causes of death were obtained from Statistics Finland for year 2015, where dementia consists of ICD-10 diagnoses F01, F03, G30, R54 [27] . Chi-square test was used to test for significance between groups.
